| 37.51 |  -0.41 / -1.08% |
Data as of 4:00pm ET | Day’s Change |
| 37.44 | -0.0681 / -0.18% |
Volume: 25.8K |
| July Options Now Available For Forest Laboratories (FRX) May 20 / TheStreet.com | Forest-Trevena Ink Deal - Analyst Blog May 14 / Zacks.com |
| Previous close | 37.92 |
| Today’s open | 37.88 |
| Day’s range | 37.44 - 38.12 |
| Volume | 1,813,292 |
| Average volume (3 months) | 1,318,027 |
| Market cap | $10.1B |
| Dividend yield | -- |
| Earnings growth (last year) | -103.36% |
| Earnings growth (this year) | +98.87% |
| Earnings growth (next 5 years) | +37.00% |
| Revenue growth (last year) | -29.49% |
| P/E ratio | NM |
| Price/Sales | 3.28 |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| PRGOPerrigo Co | -0.58 | -0.49% |
| BMRNBioMarin Pharmaceuti... | +0.55 | +0.85% |
| MYLMylan Inc | +0.33 | +1.06% |
| ONXXOnyx Pharmaceuticals... | +0.12 | +0.13% |
| Next reporting date | July 23, 2013 |
| EPS forecast (this quarter) | $0.10 |
| Annual revenue (last year) | $3.1B |
| Annual profit (last year) | -$32.1M |
| Net profit margin | -1.04% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman, President & Chief Executive Officer Howard Solomon |
Senior Vice President & Operations Director Kevin Walsh |
Corporate headquarters New York, New York |
.
